Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press108410.17650/1726-9776-2007-3-1-37-39DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. URINARY BLADDER CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак мочевого пузыряImplication of expression of the oncoprotein Her-2/neu and the intracellular matrix component tenascin for metastatic activity of urinary bladder cancerЗначимость экспрессии онкопротеина Her-2/neu и компонента межклеточного матрикса тенасцина для метастатической активности рака мочевого пузыряAndreyevaYu. Yu.АндрееваЮ. Ю.
Russian Federation
ZavalishinaL. E.ЗавалишинаЛ. Э.
Russian Federation
PetrovA. N.ПетровА. Н.
Russian Federation
FrankG. A.ФранкГ. А.
Russian Federation
P.A. Herzen Moscow Research Oncological Institute, Russian Ministry of HealthМосковский научно-исследовательский онкологический институт им. П.А. Герцена300320073137391502202015022020https://oncourology.abvpress.ru/oncur/article/view/1084

The authors conducted an immunohistochemical study with antibodies to Her-2/neu and tenascin in urothelial bladder carcinoma. The samples taken from 32 patients with stages Т2b/T3a, N0 and N+ urinary bladder carcinoma were studied. The tumor cells showed hyper-expression of the oncoprotein Her-2/neu in 6 out of 13 patients with metastases to the regional lymph nodes (T3b и T3a) and in 2 out of 7 tumors (Т3а) without lymph node involvement. Quantitative assessment of the reaction with tenascin antibodies revealed that in the metastatic lymph node involvement group, the staining area was much larger than that in metastasis-free group and it averaged 49.83 and 44.21% and 11.27 and 15.7%, respectively. Comparison analysis of Her-2/neu and tenascin expression revealed no clinically significant regularities. The study of the intercellular matrix showed a high correlation between the increase in the share of tenascin-expressing and/or containing structures and the rise in the metastatic activity of a tumor.

.

1. Coogan C.L., Estrada C.R., Kapur S. et al. Her-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology 2004;63(4):786—90.Coogan C.L., Estrada C.R., Kapur S. et al. Her-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology 2004;63(4):786—90.2. San Miguel Fraile P., Anton Badiola I., Ortiz Rey J.A. et al. [Comparative study of the expression of p53, Ki-67, bcl-2 and CK20 in superficial transitional carcinoma of the bladder: correlation with recurrence, histological grade, and clinical stage]. Actas Urol Esp 2003;27(8):587—93.San Miguel Fraile P., Anton Badiola I., Ortiz Rey J.A. et al. [Comparative study of the expression of p53, Ki-67, bcl-2 and CK20 in superficial transitional carcinoma of the bladder: correlation with recurrence, histological grade, and clinical stage]. Actas Urol Esp 2003;27(8):587—93.3. Wang C., Liu X., Wang L. et al. [p16, p53 and c-erbB-2 gene expression in bladder carcinoma] Zhonghua Bing Li Xue Za Zhi 2000;29(1):20—3.Wang C., Liu X., Wang L. et al. [p16, p53 and c-erbB-2 gene expression in bladder carcinoma] Zhonghua Bing Li Xue Za Zhi 2000;29(1):20—3.4. Levine A.I., Schmidek H.H. Molecular genetics of nervous system tumors. NY, Wiley-Liss; 1993.Levine A.I., Schmidek H.H. Molecular genetics of nervous system tumors. NY, Wiley-Liss; 1993.5. Chiquet-Ehrismann R., Kalla P., Pearson C.A. Participation of tenascin and transforming growth factor-beta in reciprocal epithelial-mesenchymal interactions of MCF7 cells and fibroblasts. Cancer Res 1989;49(15):4322—5.Chiquet-Ehrismann R., Kalla P., Pearson C.A. Participation of tenascin and transforming growth factor-beta in reciprocal epithelial-mesenchymal interactions of MCF7 cells and fibroblasts. Cancer Res 1989;49(15):4322—5.6. Lightner V.A., Erickson H.P. J Cell Sci 1990;95(Pt 2):263—77.Lightner V.A., Erickson H.P. J Cell Sci 1990;95(Pt 2):263—77.7. Herold-Mende C., Mueller M.M., Bonsanto M.M. et al. Clinical impact and functional aspects of tenascin-C expression during glioma progression. Int Cancer 2002;98(3):362—9.Herold-Mende C., Mueller M.M., Bonsanto M.M. et al. Clinical impact and functional aspects of tenascin-C expression during glioma progression. Int Cancer 2002;98(3):362—9.8. Korshunov A., Golanov A., Timirgaz V. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases. J Neurol Sci 2000;177(1):72—82.Korshunov A., Golanov A., Timirgaz V. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases. J Neurol Sci 2000;177(1):72—82.9. Kim C.H., Bak K.H., Kim Y.S. et al. Expression of tenascin-C in astrocytic tumors: its relevance to proliferation and angiogenesis. Surg Neurol 2000;54(3):235—40.Kim C.H., Bak K.H., Kim Y.S. et al. Expression of tenascin-C in astrocytic tumors: its relevance to proliferation and angiogenesis. Surg Neurol 2000;54(3):235—40.10. Brunner A., Mayerl C., Tzankov A. et al. Prognostic significance of tenascin-C expression in superficial and invasive bladder cancer. J Clin Pathol 2004;57(9): 927—31.Brunner A., Mayerl C., Tzankov A. et al. Prognostic significance of tenascin-C expression in superficial and invasive bladder cancer. J Clin Pathol 2004;57(9): 927—31.11. Ioachim E., Michael M., Stavropoulos N.E. et al. A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma. BJU Int 2005;95(4):655—9.Ioachim E., Michael M., Stavropoulos N.E. et al. A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma. BJU Int 2005;95(4):655—9.12. Завалишина Л.Э., Петров А.Н., Андреева Ю.Ю. Количественная оценка результатов иммуногистохимического исследования тенасцина в инфильтративном протоковом раке молочной железы. Арх патол 2005;(6):21—4.Завалишина Л.Э., Петров А.Н., Андреева Ю.Ю. Количественная оценка результатов иммуногистохимического исследования тенасцина в инфильтративном протоковом раке молочной железы. Арх патол 2005;(6):21—4.